Clinical Trials

200 enrolled

Prostatic Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06915025 2026-05-04

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06412120 2026-04-23

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

70 enrolled

Ovarian Neoplasms

NCT06180356 2026-04-22

ANALLISA

30 enrolled

Ovarian Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT06388733 2026-04-01

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

450 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Phase 1 Recruiting

24 enrolled

Neoplasm Metastasis

NCT05718323 2026-02-06

RAISE

44 enrolled

Thoracic

SCLC,Extensive Stage

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

120 enrolled

CNS

Brain Neoplasms

NCT03651206 2025-12-19

ROCSAN

Phase 2/3 Recruiting

138 enrolled

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

25 enrolled

Penile Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

30 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Phase 1/2 Recruiting

320 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06747845 2025-09-16

ParpVax2

68 enrolled

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04341181 2025-07-25

ProTarget

300 enrolled

Neoplasms

NCT05990192 2025-04-22

SOPRANO

42 enrolled

Ovarian Neoplasms

NCT03903835 2025-04-09

ProBio

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05784012 2025-03-13

RADIAN

Phase 1/2 Recruiting

34 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

770 enrolled

Rare Tumor

NCT04812366 2024-12-16

GUNS

315 enrolled

Prostatic Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Neoplasms

NCT04716686 2024-01-05

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

83 enrolled

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05961124 2023-11-22

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

40 enrolled

Ovarian Neoplasms

NCT06141265 2023-11-21

BRAND

116 enrolled

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

NCT04681469 2022-08-04

PRIME

49 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

167 enrolled